BRAIN Biotech AG
Gina Dunlevy is a Technical Business Development Manager at BRAIN Biotech AG, focusing on the intersection of bioscience and technical industries to promote sustainable solutions in cleantech applications, biosolutions, recycling, upcycling, and remediation. Previously, Gina served as a Scientific Project Manager, developing green technologies for mining and recycling, and a Postdoctoral Research Associate at The University of Manchester, researching microbial transformations of metals. Gina's background includes roles as a Senior Consultant and Researcher in the DACH region for Hyperion Executive Search, facilitating executive placements in the clean energy sector. Academic qualifications include a Ph.D. in Geomicrobiology and a Master's degree in Geosciences. Currently pursuing an MBA at ESMT Berlin, Gina combines technical expertise with business acumen to drive innovation in sustainability.
BRAIN Biotech AG
BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded.